LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • October 21st, 2008 • Evivrus, Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 21st, 2008 Company Industry JurisdictionTHIS LICENSE AND COLLABORATION AGREEMENT (the “Agreement”) is entered into this 26th day of July 2006 (the “Effective Date”) by and between Santaris Pharma A/S, a Danish corporation having its principal place of business at Hørsholm, Denmark (“Santaris”), and Enzon Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at Bridgewater, New Jersey 08807 (“Enzon”). Santaris and Enzon may be referred to herein individually as a “Party” or collectively, as the “Parties”.
AMENDMENT TO LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • October 21st, 2008 • Evivrus, Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 21st, 2008 Company Industry JurisdictionTHIS AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT (this “Amendment”), is entered into this 21 day of December 2007 (the “Effective Date”) by and between Santaris Pharma A/S, a Danish corporation having its principal place of business at Hørsholm, Denmark (“Santaris”), and Enzon Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at Bridgewater, New Jersey 08807 (“Enzon”). Santaris and Enzon may be referred to herein individually as a “Party” or collectively, as the “Parties”.
AMENDMENT TO LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • October 21st, 2008 • Evivrus, Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 21st, 2008 Company Industry JurisdictionTHIS AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT (this “Amendment”), is entered into this 25th day of June 2007 (the “Effective Date”) by and between Santaris Pharma A/S, a Danish corporation having its principal place of business at Hørsholm, Denmark (“Santaris”), and Enzon Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at Bridgewater, New Jersey 08807 (“Enzon”). Santaris and Enzon may be referred to herein individually as a “Party” or collectively, as the “Parties”.
CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND IS NOTED AS FOLLOWS **REDACTED**. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED SEPARATELY WITH...License and Collaboration Agreement • October 21st, 2008 • Evivrus, Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 21st, 2008 Company Industry JurisdictionTHIS AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT (this “Amendment”), is entered into this ___ day of June 2007 (the “Effective Date”) by and between Santaris Pharma A/S, a Danish corporation having its principal place of business at Hørsholm, Denmark (“Santaris”), and Enzon Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at Bridgewater, New Jersey 08807 (“Enzon”). Santaris and Enzon may be referred to herein individually as a “Party” or collectively, as the “Parties”.
LICENSE AGREEMENTLicense Agreement • July 31st, 2008 • Evivrus, Inc. • New York
Contract Type FiledJuly 31st, 2008 Company JurisdictionTHIS LICENSE AGREEMENT (the “Agreement”) is entered into this 30th day of September 2005 (the “Effective Date”) by and between NatImmune A/S, a Danish corporation with offices at Fruebjergvej 3, Box 3, DK-2100, Copenhagen, Denmark (“NatImmune”), and ENZON PHARMACEUTICALS, INC., a Delaware corporation with offices at 685 Route 202/206, Bridgewater, New Jersey 08807 (“Enzon”). NatImmune and Enzon may be referred to herein individually as a “Party” or collectively, as the “Parties.”
AMENDMENT TO LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • July 31st, 2008 • Evivrus, Inc. • New York
Contract Type FiledJuly 31st, 2008 Company JurisdictionTHIS AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT (this “Amendment”), is entered into this 25th day of June 2007 (the “Effective Date”) by and between Santaris Pharma A/S, a Danish corporation having its principal place of business at Hørsholm, Denmark (“Santaris”), and Enzon Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at Bridgewater, New Jersey 08807 (“Enzon”). Santaris and Enzon may be referred to herein individually as a “Party” or collectively, as the “Parties”.
AMENDMENT TO LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • July 31st, 2008 • Evivrus, Inc. • New York
Contract Type FiledJuly 31st, 2008 Company JurisdictionTHIS AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT (this “Amendment”), is entered into this 13th day of June 2007 (the “Effective Date”) by and between Santaris Pharma A/S, a Danish corporation having its principal place of business at Hørsholm, Denmark (“Santaris”), and Enzon Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at Bridgewater, New Jersey 08807 (“Enzon”). Santaris and Enzon may be referred to herein individually as a “Party” or collectively, as the “Parties”.
LICENSE AGREEMENTLicense Agreement • October 21st, 2008 • Evivrus, Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 21st, 2008 Company Industry JurisdictionTHIS LICENSE AGREEMENT (the “Agreement”) is entered into this 30th day of September 2005 (the “Effective Date”) by and between NatImmune A/S, a Danish corporation with offices at Fruebjergvej 3, Box 3, DK-2100, Copenhagen, Denmark (“NatImmune”), and ENZON PHARMACEUTICALS, INC., a Delaware corporation with offices at 685 Route 202/206, Bridgewater, New Jersey 08807 (“Enzon”). NatImmune and Enzon may be referred to herein individually as a “Party” or collectively, as the “Parties.”
Enzon Pharmaceuticals, Inc.License Agreement • July 31st, 2008 • Evivrus, Inc.
Contract Type FiledJuly 31st, 2008 Company
AMENDMENT TO LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • July 31st, 2008 • Evivrus, Inc. • New York
Contract Type FiledJuly 31st, 2008 Company JurisdictionTHIS AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT (this “Amendment”), is entered into this 21 day of December 2007 (the “Effective Date”) by and between Santaris Pharma A/S, a Danish corporation having its principal place of business at Hørsholm, Denmark (“Santaris”), and Enzon Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at Bridgewater, New Jersey 08807 (“Enzon”). Santaris and Enzon may be referred to herein individually as a “Party” or collectively, as the “Parties”.
INDENTURE OF LEASE BETWEEN HOLLAND REALTY CORP., Landlord and ENZON, INC., Tenant Dated: April 1, 1995Lease Agreement • September 12th, 2008 • Evivrus, Inc. • Pharmaceutical preparations • New Jersey
Contract Type FiledSeptember 12th, 2008 Company Industry JurisdictionTHIS LEASE, dated the 1st day of April 1995, between HOLLAND REALTY CORP., a Delaware corporation, with an address c/o LPC Commercial Services, Inc., 1530 Wilson Boulevard, Arlington, Virginia 22209 (hereinafter referred to as the "Landlord"); and ENZON, INC., a corporation of the State of Delaware, with offices at 20 Kingsbridge Road, Piscataway, New Jersey 08854 (hereinafter referred to as the "Tenant").
Enzon Pharmaceuticals, IncLicense Agreement • July 31st, 2008 • Evivrus, Inc.
Contract Type FiledJuly 31st, 2008 Company
Enzon Pharmaceuticals, Inc.License Agreement • July 31st, 2008 • Evivrus, Inc.
Contract Type FiledJuly 31st, 2008 Company